Company / Net Income
Unicycive Therapeutics, Inc. Net Income History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$30.5M
FY2024
5-year range
-$30.5M / -$10.0M
FY2022-FY2024
Trend
-69.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$10M to -$31M over the past 2 years.
Based on SEC 10-K filings.
-$31M in FY2024.
Declined from -$10M to -$31M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, net income decreased 69.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$30.5M | -69.1% |
| FY2023 | -$18.1M | -80.3% |
| FY2022 | -$10.0M | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026